Genomic testing for targeted oncology drugs: hopes against hype
- PMID: 33992745
- DOI: 10.1016/j.annonc.2021.05.354
Genomic testing for targeted oncology drugs: hopes against hype
Conflict of interest statement
Disclosures RD declares consultant and/or advisory role for Roche, Boehringer Ingelheim, received a speaker's fee from Roche, Ipsen, Amgen, Servier, Sanofi, Libbs, Merck Sharp & Dohme, and research grants from Merck and Pierre Fabre. DT reports consultant and/or advisory fees from Roche.
Comment on
-
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020.Ann Oncol. 2021 Jul;32(7):926-932. doi: 10.1016/j.annonc.2021.04.003. Epub 2021 Apr 20. Ann Oncol. 2021. PMID: 33862157
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
